Developed by Italian tech company, Otech Industry srl, the Onemytis 2 uniquely uses gas ionisation to vaporise tissue at lower temperatures and, claims Excel, with greater precision than is possible with conventional electrosurgery.
The knife works by a strong electromagnetic field through air. This releases plasma which vaporises tissue at a maximum operating temperature of 50°C (compared to more than 118°C in conventional electrosurgery).
During surgery, the electrode does not touch the patient. Plasma is formed when it is between 1 and 2 mm away from the patient, depending on the power setting. This means the surgeon does not apply any pressure when creating an incision, allowing greater precision.
The Onemytis range starts from £4500 +VAT.
West Sussex first opinion vet, Julian Hoad, Head of Crossways Veterinary Group, started using Onemytis last year for a range or procedures including laparoscopic surgery and the removal of masses, often without the need for a general anaesthetic.
Julian said: "I’ve used electrosurgery for 20 years and this is an order of magnitude better. It is more precise, more reliable and results in a much better healing surface."
"I recently removed an enlarged lymph node. The mass was around the mesenteric root. Because Onemytis is so precise I was able to dissect around the blood vessels, removing tissue that was attached to them with no blood loss. Onemytis is also excellent for removing epulides. It cuts though gingival tissue with very limited burning and produces very good, pain-free healing."
"I now routinely use it for performing nostril widening surgery in brachycephalic dogs; it reduces surgery time dramatically and completely abolishes bleeding in most cases."
"I have also used it to remove a large mass from a dog’s spleen and, by using a combination of Onemytis and Ligasure, managed to do so with a total blood loss of less than 2 ml."
Steve Hayden, Director at Excel Lasers, said: “We are delighted to be bringing Onemytis 2 to the UK. An important part of our role is to identify the technological innovations we think are most likely to help vets and their patients and Onemytis really stands out. The feedback we have had from our clients has been extremely positive and we think it has a fantastic future in veterinary surgery.”
To find out more about Onemytis 2 and watch videos of it in action, visit: https://www.excellasers.com/airplasma/
The RCVS Registered Veterinary Nurse Disciplinary Committee has suspended a Northants-based registered veterinary nurse who admitted to acting dishonestly with her employer, a client and a pet database company by taking home a patient that was supposed to have been euthanised.
During the two-day hearing, the Committee heard how Sally-Ann Roberts, formerly of the Best Friends Veterinary Group in Thrapston, had deliberately gone against the wishes of the owners of a 14-year-old Maine Coon cat called Jason that he be euthanised, rather than treated further, and instead had taken the cat home with her for "intensive nursing". Jason had subsequently escaped from Ms Robert's residence, leading her to fabricate a story, first to the pet database company, and then to Jason's owners and her employer, that he had escaped from the practice, before being returned by a member of the public two days later and then euthanised as originally requested.
Ms Roberts acted with her veterinary surgeon colleague Przemyslaw Bogdanowicz, who chose not to euthanise Jason and who, for his part, received a three-month suspension from the RCVS Disciplinary Committee in December 2012. She repeated the false account on a number of occasions, both orally and in written statements, and also forged the signature of Jason's owner on official documentation in order to substantiate her story.
Only when Ms Roberts was interviewed for a second time by her then employer's area manager, did she finally admit to what had actually happened. Shortly afterwards, Ms Roberts was suspended from the practice and, following an internal disciplinary hearing a few days later, was dismissed by them for gross misconduct, along with Mr Bogdanowicz. There was no evidence available as to what ultimately happened to Jason.
Explaining her actions to the Committee, Ms Roberts said she was upset that Jason's owners wanted him to be euthanised and felt that he could recover if given some love and attention. She had asked Mr Bogdanowicz to discuss this possibility with Jason's owners, but he had refused, agreeing instead that she could continue Jason's treatment at her home. After Jason escaped, Ms Roberts said she was "devastated" and had "panicked", inventing the story of Jason's escape to cover her actions, which she now acknowledged were "wrong" and "stupid", and which she "bitterly regretted". Ms Roberts expressed sorrow and remorse for her behaviour, which she said would never occur again, and stated that being a veterinary nurse was everything to her.
In view of the admitted facts, the Committee judged that Ms Robert's dishonesty and breach of client trust, as well the distinct risk of injury to which she exposed Jason, amounted to serious professional misconduct. In deciding on an appropriate sanction, the Committee balanced a number of aggravating factors (in particular, the forged signature) against Ms Roberts' "strong mitigation", which included her admitting the entirety of the charges against her, her medical and personal problems at the time, the insight she had shown into the effects of her actions on Jason's owners and her previous unblemished career.
Professor Peter Lees, chairing and speak on behalf of the Committee, said: "The Committee has concluded that the Respondent has shown insight into the seriousness of her misconduct and that there is no significant risk of repeat behaviour. In light of the Respondent's admission, her insight, her remorse and the high regard in which she is held by her professional colleagues, it is the Committee's view that the sanction of two months' suspension is appropriate and proportionate."
The Committee's full decisions on facts and sanction are available at www.rcvs.org.uk/disciplinary.
At the hearing, the Disciplinary Committee considered whether she had accepted the findings of the Committee at the original inquiry hearing, the seriousness of those findings, whether she had demonstrated insight into her past conduct, and the protection of the public and the public interest.
In her restoration application, Dr Burrows included continuing professional development (CPD) certificates for the courses she had completed since her removal from the Register, letters/informal witness statements from the veterinary surgeons and nurses she had worked who had expressed a willingness to employ her again, together with character references and reflection statements.
She also made a detailed opening statement in support of her application, in which she said that the period since her name was removed from the Register was extremely difficult and also that she now unconditionally accepted all the Committee’s original findings in May 2021, some of which she had previously denied and had failed to acknowledge.
Dr Burrows went on to state that she only had herself to blame for her actions and that she now understood and accepted that the original sanction of removal from the register had needed to be severe given the serious breach of trust to the public, to the veterinary profession and the insurance industry that was a direct consequence of her dishonest actions.
Since removal from the Register, Dr Burrows had taken on the role of receptionist in a Vets4Pets practice in Cardiff, which required her to deal directly with the public and their insurance requests and entitlements.
She stated that as a result of her involvement over the past 18 months in processing insurance claims, she acknowledges the “delicate” relationship between veterinary surgeons, clients and insurers.
Additionally, working as a receptionist, had allowed her to recognise the need for contemporaneous and clear clinical notes.
She also highlighted her CPD, which was relevant to insurance, as well as the fact she’d undertaken a professional ethics course to assist her rehabilitation, reflection, and insight.
In support of Dr Burrows’ restoration to the Register, the Committee took into account three witness accounts from people who work at the Vets4Pets branch where Dr Burrows works as a receptionist.
All witnesses gave positive reflections on Dr Burrows’ character and assured the Committee that they would provide the correct level of support to allow her to return to work safely and that they would have all the necessary safeguarding measures in place to ensure that the public’s and the profession’s interest is always at the forefront.
Judith Way, chairing the Disciplinary Committee and speaking on its behalf, said: “The Committee was impressed by the fact that busy professionals chose to give up their time to provide witness statements and give evidence in support of Dr Burrows’ application.
"All witnesses were clearly supportive of Dr Burrows’ request for restoration to the Register.
“The Committee found Dr Burrows to show remorse and she does now accept the findings of dishonesty that were made against her in the original enquiry hearing and stated that her conduct was dishonest.
"In the Committee’s view, the evidence given by Dr Burrows on affirmation was very believable and she now accepts her dishonesty together with the gravity of her dishonesty.
“The Committee also formed the view that the steps she has taken to address her dishonesty serve to confirm that she is passionate about the prospect that she be allowed to return to practise.
"The Committee was impressed by Dr Burrows and the evidence given and is now satisfied that she will ensure the highest standards of probity and honesty in the future.
“Having taken all evidence into account, the Committee is satisfied that the future welfare of animals under Dr Burrows’ responsibility will be properly protected, and that her future dealings with insurers will be honest in all respects and that the interests of the public will be met.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
The study “Hypoadrenocorticism in dogs under UK primary veterinary care: frequency, clinical approaches and risk factors1”, identified dogs diagnosed with hypoadrenocorticism from the electronic patient records of practices participating in the UK VetCompass programme during 2016.
The study aimed to estimate the frequency of hypoadrenocorticism in dogs under primary veterinary care in the UK, describe the diagnosis and clinical management of hypoadrenocorticism and report the risk factors for the disease.
Cases were categorised as having a laboratory-confirmed or presumed diagnosis, based on the information available in the electronic patient records. Multivariable logistic regression was used to identify demographic risk factors.
A total of 177 hypoadrenocorticism cases were identified from 905,543 dogs in 2016; 72 laboratory-confirmed and 105 presumed. The one-year period prevalence for hypoadrenocorticism in all dogs was 0.06%.
The most commonly recorded clinical signs included:
Imogen Schofield, corresponding author for the paper, said: “By presenting epidemiological data on dogs with hypoadrenocorticism attending primary-care practice, this study provides representative and relatable information for vets working in primary-care practice in the UK. It should be borne in mind that diagnostic and clinical management data were reported for laboratory-confirmed cases only.
“Breed, age, neuter status and insurance status were all associated with a laboratory-confirmed diagnosis of hypoadrenocorticism. The standard poodle had 51.38 times the odds of hypoadrenocorticism compared with crossbreeds. The labradoodle (OR: 7.40) and West Highland white terrier (OR: 5.84) also had increased odds.
Nicola Di Girolamo, Editor of JSAP, said: “This is the largest study to date to provide benchmark data on hypoadrenocorticism in dogs under primary veterinary care in the UK. Given that the frequency of hypoadrenocorticism has rarely been reported, it is typically difficult to diagnose due to the non-specific clinical signs associated with the disease, and many previous studies have focussed on referral populations. This is a welcome publication adding to the evidence base of an important topic.”
The full article can be found in the May issue of the Journal of Small Animal Practice and can be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13285. It is open access and can be freely accessed by anyone.
Reference
For the study1, the authors Lucy Norris, Gina Pinchbeck, Peter-John Noble and Alan Radford, analysed data from electronic health records submitted by veterinary practices participating in the Small Animal Veterinary Surveillance Network (SAVSNET).
They found that a total of 132 dogs with cropped ears were seen by vets across a sample size of 500 practices between 2015 and 2022, with numbers peaking in 2021.
The breeds most likely to have cropped ears were the American bulldog, Dobermann, Italian mastiff and bulldog.
In more than 60% of the cases, the dogs had been imported from countries where ear cropping is illegal, such as Romania, Hungary, Bulgaria, Serbia, Spain, Poland and Ireland.
The authors acknowledge that the findings of their research are likely just a small snapshot of the true scale of the ear cropping problem: figures from the 2022 PDSA PAW Report suggest that the true numbers of dogs imported with cropped ears could be as high as 26,000.
RSPCA Head of Companion Animals Samantha Gaines said: "The study provides strong evidence to refute arguments for ear cropping to prevent ear infections, as the breed types identified in Norris and colleagues’ study are not generally predisposed to such infections.
"Rather, this finding adds weight to anecdotal evidence suggesting that the motivation for ear cropping in many dogs is driven by appearance rather than any perceived health benefits.
“It is also possible that some dogs were cropped illegally in the UK using legal importation as a smokescreen for this activity.
"Indeed, it is the RSPCA's experience that many dogs stated as being cropped outside of the UK have histories that would make this highly unlikely.”
Vet Record editor-in-chief Suzanne Jarvis said: “One solution to the importation problem is proposed in the Kept Animals Bill, which is currently stalled in parliament.
"Although there could be potential for fraud around grandfather rights initially, a ban on such importations would ultimately mean that the sight of a dog with cropped ears becomes a thing of the past in the UK.”
https://www.bva.co.uk/take-action/ear-cropping-campaign
The practical, wet lab, small group and 'Breakfast with a Specialist' programme has expanded to enhance the CPD experience and to meet rising demand, alongside more than 450 lectures for delegates to choose from.
Wet lab sessions, introduced at Congress 2017, will again be held at the University of Birmingham’s Medical School and include topics on cytology, haematology, basic eye surgery, rabbit dentistry and dental radiography for dogs and cats.
'Breakfast with a Specialist' sessions give delegates exclusive access to world-renowned experts to discuss challenging cases informally, in a small group setting: endocrinology cases with David Church on Friday, epilepsy cases with Holger Volk on Saturday and jaw fracture fixation in the dog and cat with Peter Southerden on Sunday.
BSAVA Congress Programme Committee Chair Sue Murphy said: "Responding to the excellent delegate feedback from 2017’s programme, we are increasing the number of practical and small group sessions to enable more delegates to benefit in 2018. These sessions represent excellent, value for money education and a unique opportunity for delegates to practice vital skills with guidance from experts in their respective disciplines.’"
Each workshop or small group is available to purchase when registering for Congress and a full summary of each practical and small group session is available at: http://www.bsavacongress.com/programme
The 61st annual BSAVA Congress takes place at the Birmingham ICC and Arena Birmingham from 5-8 April, including a new non-clinical stream on Sunday – Beyond the Clinics.
The research is being carried out by Cats Protection, RSPCA, PDSA, Wood Green The Animal Charity, Blue Cross, Celia Hammond Animal Trust, Battersea, The Mayhew Animal Home, SSPCA and International Cat Care, with support from Bristol University.
The study involves four short (<15 minute) questionnaires spread over a 6-month period, for which you could also win a £50 voucher.
Click here to find out more and sign up www.surveymonkey.co.uk/r/neutering
Cryptisel is for use in reducing oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem. After the presence of the causal organism has been established, Forte says Cryptisel can be used in all new-born calves to break the cycle of transmission and multiplication on-farm.
Dr John Henderson, Large Animal Product Manager with Forte Healthcare Ltd said: "Cryptisel will be a very useful medicine in the control of the most commonly-identified scour pathogen in the UK and Ireland. Used alongside the calf-rearing cornerstones of good colostrum management, hygiene, and biosecurity, Cryptisel will reduce production of Cryptosporidium oocysts and help limit spread of the disease among susceptible calves."
Cryptisel is a POM, available in 490ml and 980ml bottles. Both sizes come with a metered dosing pump for convenient administration.
For further information, contact your local Forte Territory Manager or email enquiries@fortehealthcare.com.
Matt has taken over as hospital director from David Walker, who has now moved to the role of referrals managing director in the south of the UK for Linnaeus.
Matt said: “I certainly have some big shoes to fill but working as clinical director alongside David was a great grounding and we work well together.
“Essentially, I was his running mate back then but now I am stepping up to take on the main role, with all the additional responsibilities it entails, and I’m determined to make it my own.
“I know I have the drive, the desire, the clarity of purpose and the dedication to succeed.
"I also know what an incredible operation I have inherited from David.
“One of the key things about Anderson Moores is that every member of the team works together in the same location to support every aspect of a pet’s treatment and recovery, so whatever service they may need is all available under the same roof.”
www.andersonmoores.com/homewww.zeropainphilosophy.com
The RCVS is seeking feedback on a new draft Code of Professional Conduct.
The new Code, which would replace the existing RCVS Guide to Professional Conduct for Veterinary Surgeons, has been produced by a Working Party set up by the RCVS Advisory Committee to review the Guides for both veterinary surgeons and veterinary nurses.
According to the College, the purpose of the review, which last took place over a decade ago, is to ensure guidance to the profession and the public is clear. For example, using consistent language to distinguish between what must be done and what is advised.
The RCVS says the new Code is a short, principles-based document using the Federation of Veterinarians of Europe's Code of Conduct as the starting point. It will be supported by additional advice on specific areas of veterinary practice or issues, for example, clinical governance. It also includes:
Clare Tapsfield-Wright, Chairman of the Guides Review Working Party said: "Over the decade or so since it was last reviewed, not only has the Guide become unwieldy in places, but the way that regulators in general publish professional conduct rules has changed. Our draft new Code aims to clarify matters and bring us into line with best practice elsewhere.
"Animal owners are increasingly keen to understand the basis of what the veterinary profession considers to be good professional conduct. The new simplified Code should assist with this understanding."
The new Code, together with the consultation paper, can be downloaded at http://www.rcvs.org.uk/codeconsultation
Comments, which are welcomed from the profession and the public, should be sent by email to Christopher Murdoch, Secretary to the Guides Review Working Party, at c.murdoch@rcvs.org.uk by Friday, 24 June 2011.
A separate document is under development for veterinary nurses, which will share broadly similar underlying principles and will be the subject of its own consultation.
The committee heard five charges against Dr Davies at a resumed hearing of an inquiry which was originally adjourned in January and then July 2018. The decision was made, at both the 2018 hearings, to postpone the final decision on the sanction.
The first two charges against Dr Davies related to convictions for drink driving in March 2014 and October 2015 for which she received driving bans of 17 and 45 months.
The third charge related to her breaching a number of undertakings she had entered into as part of the College’s Health Protocol, including her consuming alcohol on four occasions between May 2015 and January 2016 and missing a pre-arranged appointment with a consultant psychiatrist appointed.
The fourth and fifth charges related to being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016 which was also in breach of her undertakings under the Health Protocol.
At Dr Davies' first Disciplinary Committee hearing in January 2018, she admitted all five charges against her and also accepted that her conduct was disgraceful conduct in a professional respect.
The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At the conclusion of its hearing on 23 January 2018 the Committee decided to postpone its decision regarding sanction for six months on the basis of Dr Davies’ entering into undertakings, including not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement and to undergo blood and hair tests for alcohol consumption every two months.
At the resumed hearing on 30 July 2018, Dr Davies’ Counsel submitted on her behalf that she wished to return to practise and the Committee reviewed evidence that she provided to demonstrate she had complied with her undertakings.
However, the Committee retained concerns about Dr Davies' return to practise and therefore required her to identify a veterinary surgeon who would agree to act as her mentor, noting that the mentor would have to be acceptable to the College as someone suitable to act in that capacity.
The Committee also required the continuation of the requirements for abstinence from alcohol and the programme of blood and hair testing.
A further requirement of the Committee was that Dr Davies should make a disclosure to any new employer of her appearances before the Committee in January 2018 and in July 2018 and of the decisions it made.
The final requirement of the Committee was that the respondent should not accept a ‘sole charge position’ at any time during her employment during this next period of postponement of sanction. The Committee then directed that the hearing be postponed for a further 12 months.
The Disciplinary Committee resumed its inquiry on 7th August 2019, when Dr Davies submitted documentary proof and medical records to demonstrate she had complied with all her undertakings given at the last hearing. The Committee also heard from Dr Davies’ appointed veterinary mentor who provided a statement that concluded that she no longer needed monitoring or supervision.
The Committee then considered what sanction to impose on Dr Davies.
Ian Green, chairing the Committee and speaking on its behalf, said: "The view of the Committee is that the respondent has to date overcome her addiction to alcohol and, given that her competence as a practising veterinary surgeon is not disputed, that she should therefore be permitted to return to her chosen profession. However, in the judgment of this Committee the seriousness of the offences to which the Respondent has pleaded guilty means that a sanction of “No Further Action” cannot be justified."
The Committee therefore decided that the most proportionate sanction was for Dr Davies to be reprimanded as to the conduct she admitted at previous hearings and that she be warned as to her future conduct.
Ian added: "The respondent must understand that she has been given an opportunity to prove that, for the remainder of her time in practice, she can meet the high standards expected of all registered veterinary surgeons from both other practitioners and from members of the public who entrust the care and treatment of their animals to members of this profession."
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
There are 10 candidates standing in this year’s election, including four existing Council members eligible for re-election and six candidates not currently on Council. They are:
Mr David Catlow MRCVS
John C Davies MRCVS
Dr Mandisa Greene MRCVS
Miss Karlien Heyrman MRCVS
Professor John Innes FRCVS
Dr "Not Again" Thomas Lonsdale MRCVS
Dr Susan Paterson FRCVS
Mr Matthew Plumtree MRCVS
Mr Iain Richards MRCVS
Colonel Neil Smith FRCVS
The biographies and statements for each candidate can be found at www.rcvs.org.uk/vetvote18.
At the time of writing, the College is still waiting for the Legislative Reform Order (LRO) concerning its governance arrangements, including a reduction in the size of Council, to be approved.
Under current arrangements six candidates will be elected to RCVS Council – however, if the LRO completes the legislative process and is passed by both Houses of Parliament, then only the three candidates with the most votes will take up their places on Council.
Ballot papers and candidates’ details are due to be posted to all veterinary surgeons eligible to vote during the week commencing 12 March, and all votes must be cast, either online or by post, by 5pm on Friday 27 April 2018.
Once again this year the College is inviting veterinary surgeons to email a question for the candidates to vetvote18@rcvs.org.uk or tweet it using the hashtag #vetvote18 by midday on Monday 26 February.
Each candidate will then be asked to answer two questions from all those received, and produce a video recording of their answers. Recordings will be published on the RCVS website and YouTube channel (www.youtube.com/rcvsvideos) on the week the election commences.
Eleanor Ferguson, RCVS Registrar, said:"After last year’s record turnout in the RCVS Council elections we are continuing to work with Electoral Reform Services (ERS) to make it easier for members to vote for their preferred candidates.
"While the traditional paper ballot papers and booklets will be posted as usual, ERS will once again send personalised emails linking members to their unique secure voting website and then send regular reminders to those who haven’t yet had the chance have their say."
Jon Pycock, President of BEVA said: "A significant number of BEVA members have young children and we want to make it as easy as possible for them to enjoy Congress without having to worry about making separate plans for childcare at home. We have already had a great response to the idea and it’s looking like the crèche is going to be very popular."
The theme of this year's Congress is helping horse vets celebrate the benefits and pleasures of their job.
In addition to the social and scientific programme at Congress, there will be special sessions on reproduction, non-clinical aspects of being a vet, succession planning, a moral maze debate on specials manufacturing and role play demonstrations on how to manage difficult situations in practice.
Dr Juan Samper, Associate Dean for students and instruction at the University of Florida College of Veterinary Medicine will be giving the plenary lecture on the challenges and opportunities in equine practice.
There will also be specific lecture streams for veterinary nurses, equine dental technicians and farriers.
For more information on the BEVA Congress crèche or to reserve your child's place, contact Jocelyn@beva.org.uk or call 01638 723558. BEVA says places are limited so early booking is advised.
The BEVA Congress programme can be viewed at www.bevacongress.org.
A survey carried out by Rachel Crowe BSc PhD in association with Virbac Animal Health and VetSurgeon.org has revealed what veterinary surgeons in the UK expect from pharmaceutical companies and other suppliers.
The survey considers a number of different aspects of the relationship between vets and pharmaceutical companies, from the importance of quality products through to the question of what vets expect from company representatives.
Chris Liggett, Marketing Director at Virbac UK said: "The findings of this survey offer a fascinating insight into the relationship between veterinary practices and their suppliers. In some ways they confirm what we should all already know - that the quality of a company's product range is paramount and that representatives play a key role as ambassadors for our businesses - but the growing importance to vet practices of working with drug companies that provide a complete package of products and services is worthy of note."
The full report is available to download here.
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
The Kennel Club is calling on the profession to support Get Fit With Fido, its new campaign to help tackle the growing dog obesity crisis by educating owners about the range of different ways to get fit with their dogs..
In addition to the education campaign, Get Fit With Fido also includes a challenge that rewards the dog and dog owner who jointly lose the most weight, and the dog owner and dog who individually lose the most weight, as a result of exercising together. Prizes include a one night stay at the dog friendly, 4* boutique townhouse hotel Flemings Mayfair; a luxury dog bed from Charley Chau and Champagne Afternoon Tea for Two at the Milestone Hotel.
All dog owners who enter Get Fit With Fido, will receive a 20% discount on Crufts and Discover Dogs tickets; as well as advice, tips and tools for owners.
Veterinary practices are being asked to support the campaign by requesting free flyers and posters from the Kennel Club and then displaying them at reception, or in the waiting room.Caroline Kisko, Kennel Club Secretary, said: "Reports indicate that between 30 and 60% of all dogs are overweight so it is more important than ever we keep our dogs happy and healthy. One of the most serious findings in obesity studies that have proven to be related to being overweight in both humans and dogs is a reduced lifespan. An overweight dog is more likely to die younger than a dog of normal weight.
"The findings are shocking and we are trying to educate as many dog owners as possible and call on vets to spread the message of keeping your dog fit and healthy."
To get involved in Get Fit With Fido and receive free flyers and posters, contact the Kennel Club press office at gfwf@thekennelclub.org.uk
For more information, visit www.thekennelclub.org.uk/getfitwithfido
The British Veterinary Association has welcomed the tightening up of sales of veterinary medicines on the internet but has expressed disappointment that the advertising of antimicrobials to farmers will continue.
The Veterinary Medicines Directorate has today published its response to the public consultation on the Veterinary Medicines Regulations, which are updated every year.
The new Regulations, which come into force in April 2011, introduce new controls on internet pharmacies meaning that only approved websites will be legally allowed to dispense and supply veterinary medicines. The controls will come into force in April 2012 and the BVA supports the use of a logo on approved websites to help consumers buy medicines from reputable sources.
The BVA has previously expressed concern that pet owners could inadvertently buy counterfeit veterinary medicines online and urges veterinary clients to seek advice from their vet and only buy from UK-based companies.
Harvey Locke, President of the BVA, said: "Without proper regulation online pharmacies could be sourcing drugs from overseas and selling counterfeit medicines that look genuine to unsuspecting pet owners. These medicines are placebos at best and dangerous at worst.
"We therefore welcome the VMD's decision to clampdown on irresponsible online retailers and provide a clear logo for approved websites that will give pet owners confidence.
"We have also asked the VMD to put a stop to the increasing problem of prescription fraud and we hope the tighter regulation announced today will be a step towards achieving that aim.
"However, we would urge all pet owners to continue talking to their vet about sourcing medicines from the internet to make sure the right drugs are bought and administered correctly."
In light of increasing concerns about the growth of antimicrobial resistance the VMD's consultation canvassed views on restricting the advertising of antimicrobials to farmers. The BVA says it supported a ban on advertising as a sensible approach to the responsible use of antimicrobials, and is disappointed that the VMD has decided not to go ahead with it. Mr Locke said: "New antimicrobials are heavily advertised by pharmaceutical companies to vets and farmers so it is vital that the message of responsible use is not lost.
"Antimicrobial resistance is a serious issue for both animal and human health and we are disappointed that the VMD is not restricting the advertising of these products to farmers. The pharmaceutical companies must now undertake to advertise responsibly.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets and farmers should work together to ensure antimicrobials are used prudently and responsibly."
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
The RCVS Disciplinary Committee has directed that the name of a veterinary surgeon who formerly practised in Norwich should be removed from the Register, having found him unfit to practise veterinary surgery following his Crown Court conviction for fraud.
During the one-day hearing, the Disciplinary Committee heard how Francisco da Cruz had abused his position whilst practising as a veterinary surgeon at Hellesdon Vets, his then workplace in Norwich, by defrauding a insurance companies of around £10,000 with fictitious claims for veterinary treatment on non-existent pets.
Following an investigation by the City of London Police's Insurance Fraud Enforcement Department (IFED), Mr da Cruz was convicted on five counts of fraud by false representation on 21 February 2013 at the Old Bailey in London, and later sentenced to eight months' imprisonment (suspended for two years) and 200 hours of unpaid community work; he was also ordered to pay just over £10,000 in compensation and costs.
Although Mr da Cruz had left the UK for Brazil shortly after his sentencing and was therefore not present at the hearing, the Committee was satisfied that he was deliberately evading the disciplinary proceedings, rather than being genuinely unable to participate in them, and so the hearing proceeded in his absence.
First accepting the copy certificate of conviction against Mr da Cruz as true, the Committee then had no hesitation in concluding that these convictions rendered him unfit to practise as a member of the veterinary profession. It found that the five counts of fraud were deliberate crimes of dishonesty, committed over a significant period of time and for significant financial gain. He had abused his position as a veterinary surgeon and abused the trust which the insurers placed in him as a professional.
Chairing and speaking on behalf of the Committee, Professor Peter Lees, said: "The Committee has no real confidence that there is no significant risk of repeat behaviour from the Respondent. His conduct subsequent to the criminal proceedings gives it no confidence that he has reformed himself to the extent that he will in the foreseeable future be fit to return to practice. So far from satisfactorily completing his criminal sentence, it appears that the Respondent has deliberately gone abroad to avoid doing so."
Bearing in mind that the purpose of any sanction it imposed was not to punish Mr da Cruz, but to maintain public confidence in the profession and uphold proper standards of conduct within it, the Committee concluded that the convictions were too serious to allow any sanction other than removal from the Register.
The full details of the Committee's decisions are available on the RCVS website (www.rcvs.org.uk/disciplinary).
What is 'quality improvement', you ask? Good question. Sure, it's an improvement in, er, quality. But of what?
'Quality improvement' is a term adopted from the human healthcare sector, variously defined as anything which makes: "healthcare safer, effective, patient-centred, timely, efficient and equitable (NHS)", or "the combined and unceasing efforts of everyone—healthcare professionals, patients and their families, researchers, payers, planners and educators—to make the changes that will lead to better patient outcomes (health), better system performance (care) and better professional development (BMJ)."
The RCVS research project, which is being conducted by RAND EUROPE, will assess current perceptions and adoption of quality improvement in the veterinary profession.
Specifically, it'll look at the drivers, barriers and expectations associated with QI, with the ultimate goal of strengthening the support provided to the profession.
Chris Gush, Executive Director of RCVS Knowledge, said: "We are delighted to be launching this research project with RAND Europe.
"We know that many of our colleagues across the profession have embedded quality improvement into their practice to great benefit, while we are also aware that it can be a challenge to do so all of the time.
"This research will provide an unprecedented body of evidence on the experiences and perceptions of QI, which will be critical to how we work to support the sector in this area going forward."
Integral to the research is a survey which all members of the profession are invited to take part in, here: bit.ly/QIvetsurvey.
The survey will be live for six weeks, closing early April. It takes around ten minutes to complete, with a prize of one £150 Amazon voucher on offer. Responses will be anonymised.
You can read more about Quality Improvement on the RCVS Knowledge website, here: https://knowledge.rcvs.org.uk/quality-improvement/
Anna, who has been with the Hertfordshire-based referral centre for seven years, is now an RCVS, EBVS and American Specialist in Small Animal Internal Medicine.
She graduated from The University of Liverpool in 2007 and spent four years working in general practice in Kent.
She then went on to complete a rotating internship, followed by a residency in Small Animal Internal Medicine at the Royal Veterinary College where she gained her Master’s degree and Diploma.
Whilst enjoying all aspects of Internal Medicine, she has special interests in endocrinology and haematology. The latter, combined with her love for cats, has fuelled her interest in feline transfusion medicine.
Anna said: “I am delighted to have been appointed as Head of Internal Medicine at Davies.
“The Internal Medicine team are the detectives who work to establish a diagnosis, and we often have the added bonus of working closely with other disciplines in our multi-disciplinary environment.
"It is a challenging and highly rewarding service, with a wide variety of cases and I am delighted to work with a first-class team of clinicians and nurses.”
The AHT has published the first research paper of its kind which looks at idiopathic epilepsy (IE) in the Italian Spinoni, a breed where the prevalence of IE has been found to be 5.3%, compared to 0.6% estimated to be seen in dogs generally in UK first opinion practice.
Dr Luisa De Risio, Head of Neurology at the AHT and lead researcher on the paper, said: "Idiopathic epilepsy is the most common chronic neurologic disorder in dogs but it can be more common in some breeds than others, for example Irish Wolfhounds, Border Collies and Italian Spinoni. Sadly, we see a lot epileptic dogs in our clinic, including these breeds as well as Golden Retrievers and Labrador Retrievers, so research being undertaken at the AHT, and around the world, is very important in helping owners of dogs with epilepsy to be able to control the effects of the disease.
"The Italian Spinone is a wonderful breed but is highly affected by idiopathic epilepsy. To our knowledge, no one has conducted such a large-scale research study in this breed to be able to gain a better understanding of how the epilepsy manifests, how prevalent it really is and, importantly, which factors may contribute to survival in these dogs.
"With the backing of the Italian Spinone Club of Great Britain, the AHT was able to design a questionnaire for the research study and work with the Kennel Club to invite over 3,000 Kennel Club registered Italian Spinone owners to aid our research by completing the questionnaire.
"1,192 owners participated in the research and of this sample, 63 Italian Spinoni had IE. Owners of affected dogs were then invited to complete a further questionnaire and asked to make the dog's medical records available. This gave us a very large amount of data to analyse from which we were able to glean a lot of very useful information about the clinical characteristics of idiopathic epilepsy in Italian Spinoni."
The research also looked at survival times of those dogs in the study with IE. Survival was significantly longer in Italian Spinone with no cluster seizures and in Italian Spinone in which antiepileptic medication was initiated after the second seizure rather than after more than three seizures.
Luisa continued: "From this sample we were able to conclude that idiopathic epilepsy in this breed often has a severe presentation but starting treatment with antiepileptic medication after the second seizure, and aggressive treatment of cluster seizures, may improve the survival of these dogs.
"The input in treatment design and modulation by a specialist veterinary neurologist with expertise in canine epilepsy can help to optimise treatment success and the dog's quality of life.
"We hope these findings will help to increase veterinary knowledge and understanding of this horrible disease and give Italian Spinoni, and other affected breeds, the best chance of fighting IE.
"Epilepsy is one of the most complex and difficult diseases to treat, with several variables in any case, but it is important for owners not to give up hope and to seek a consultation with a veterinary neurologist who specialises in epilepsy, if possible."
The next phase of the AHT's research in the Italian Spinone is to identify the genetic basis of this condition, with the aim of identifying the genetic mutations responsible so that a genetic test could be created. This research is currently on-going in Italian Spinoni and Border Collies and requires more DNA samples from affected and unaffected dogs.
Luisa said: "A genetic test is the only way to successfully help breeders identify carriers and select matings which are most likely to produce unaffected dogs. However, the genetics, like the condition itself, are very complex so the development of such a test is still likely to be many years away. The most we can do for these lovely dogs now is to share these findings across the veterinary profession and to do our best to treat each dog as well as we can."
The full paper is titled 'Idiopathic Epilepsy in the Italian Spinone in the United Kingdom: Prevalence, Clinical Characteristics, and Predictors of Survival and Seizure Remission' and is published in the Journal of Veterinary Internal Medicine on an open-access basis.
Photo: © Caroline Granycome
Zoetis says Lokivetmab targets and neutralizes canine interleukin-31 (IL-31), a cytokine associated with atopic dermatitis which sends the itch signal to the brain.
The company has submitted an application for marketing authorisation of the product, which is conditionally licensed in the US and Canada under the name Canine Atopic Dermatitis Immunotherapeutic, in the European Union.
The new data was presented at the 8th World Congress of Veterinary Dermatology (WCVD).
Supporting the efficacy of Lokivetmab in canine AD, Zoetis presented the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) and other clinical signs associated with atopic dermatitis in dogs.
Veterinary investigators at 15 clinics enrolled 245 client-owned, live-at-home dogs with chronic atopic dermatitis. Lokivetmab or a placebo was administered by subcutaneous injection on day 0, and efficacy was evaluated periodically over 56 days. Dog owners assessed their dog’s pruritus using a visual analog scale (VAS), and investigators assessed the associated skin lesions using Canine Atopic Dermatitis Extent and Severity Index-03 (CADESI-03) scores.
Lokivetmab, injected once subcutaneously, provided dose-dependent improvement in owner-assessed pruritus and clinician-assessed CADESI-03 scores for four to six weeks in dogs with atopic dermatitis.
Zoetis also presented results of a randomized, double-blind, placebo-controlled trial to assess the safety of lokivetmab at the nominal dose tested of 1 mg/kg (range, 1-3.3 mg/kg) in the treatment of canine atopic dermatitis. Veterinary surgeons evaluated 245 client-owned, live-at-home dogs with chronic, naturally-occurring atopic dermatitis. These dogs were randomized at a 2:1 ratio to receive two monthly injections of lokivetmab (162 dogs) or placebo on days 0 and 28.
No immediate hypersensitivity reactions were observed and there were no clinically important differences in clinical pathology results. No apparent adverse drug interactions were reported. Dogs studied were taking a wide variety of medications, which is important because multimodal therapy is commonly prescribed for dogs with atopic dermatitis. Adverse events were reported at a similar frequency between the groups.